UBS AM
SNDX icon

UBS AM’s Syndax Pharmaceuticals SNDX Stock Holding History

UBS AM’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.53M Buy
161,323
+11,526
+8% +$240K ﹤0.01% 1786
2026
Q1 		$3.5M Buy
149,797
+7,390
+5% +$161K ﹤0.01% 1757
2025
Q4 		$2.99M Buy
142,407
+8,146
+6% +$142K ﹤0.01% 1712
2025
Q3 		$2.07M Sell
134,261
-121,877
-48% -$1.6M ﹤0.01% 1733
2025
Q2 		$2.4M Buy
256,138
+55,442
+28% +$610K ﹤0.01% 2069
2025
Q1 		$2.47M Buy
200,696
+30,596
+18% +$432K ﹤0.01% 1889
2024
Q4 		$2.25M Buy
170,100
+32,653
+24% +$559K ﹤0.01% 1979
2024
Q3 		$2.65M Sell
137,447
-15,913
-10% -$329K ﹤0.01% 1897
2024
Q2 		$3.15M Buy
153,360
+56,527
+58% +$1.18M ﹤0.01% 1749
2024
Q1 		$2.3M Buy
96,833
+3,766
+4% +$84K ﹤0.01% 1621
2023
Q4 		$2.01M Buy
93,067
+16,404
+21% +$252K ﹤0.01% 1684
2023
Q3 		$1.11M Buy
76,663
+22,981
+43% +$435K ﹤0.01% 1903
2023
Q2 		$1.13M Hold
53,682
– – ﹤0.01% 1941
2023
Q1 		$1.13M Sell
53,682
-4,413
-8% -$110K ﹤0.01% 1941
2022
Q4 		$1.48M Buy
58,095
+14,792
+34% +$345K ﹤0.01% 1673
2022
Q3 		$1.04M Sell
43,303
-2,954
-6% -$66.3K ﹤0.01% 1942
2022
Q2 		$890K Buy
46,257
+7,385
+19% +$123K ﹤0.01% 2035
2022
Q1 		$676K Hold
38,872
– – ﹤0.01% 2342
2021
Q4 		$851K Hold
38,872
– – ﹤0.01% 2300
2021
Q3 		$743K Sell
38,872
-3,800
-9% -$63.3K ﹤0.01% 2310
2021
Q2 		$733K Buy
42,672
+4,285
+11% +$78.5K ﹤0.01% 2371
2021
Q1 		$858K Buy
38,387
+12,187
+47% +$275K ﹤0.01% 2161
2020
Q4 		$583K Buy
+26,200
New +$543K ﹤0.01% 2248

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

UBS AM's SNDX Position: Q2 2026 in Review

UBS AM increased its Syndax Pharmaceuticals (SNDX) stake by 7.7% in Q2 2026, buying an estimated $240K and bringing the position to 161,323 shares worth $3.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1786.

UBS AM first reported a position in SNDX in Q4 2020 and has held it in 23 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • UBS AM held 161,323 shares of Syndax Pharmaceuticals worth $3.53M as of Q2 2026.
  • UBS AM bought 11,526 Syndax Pharmaceuticals shares in Q2 2026, an estimated $240K.
  • Syndax Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1786 holding.
  • UBS AM first reported a position in Syndax Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.